Editas Medicine, Inc. 8-K

What Happened

• On May 14, 2026, Editas Medicine announced new preclinical results at the ASGCT 2026 Annual Meeting and furnished a press release (Exhibit 99.1) in an 8‑K. The company reported that a single dose of its in vivo candidate EDIT‑401 produced a mean LDL cholesterol (LDL‑C) reduction of 90% or greater across all dose groups in non‑human primates, with effects durable through about six months.

Key Details

• Single-dose LDL‑C reduction: ≥90% mean decrease across dose groups in non‑human primates.
• Editing and protein change: 10–40% functional editing of LDLR alleles yielded a ≥6-fold mean increase in hepatic LDLR protein.
• Dose and durability: Evaluated dose range 1.5 mg/kg–3.0 mg/kg; LDL‑C lowering was rapid and durable through ~6 months.
• Safety and biodistribution: No adverse clinical observations at the therapeutically relevant 1.5 mg/kg dose; highest delivery to hepatocytes and undetectable delivery to oocytes.
• Additional preclinical support: Mouse studies (heterozygous Ldlr LOF and wildtype) suggest dose adjustments may not be required for heterozygous familial hypercholesterolemia (HeFH) patients.

Why It Matters

• These are preclinical (non‑human primate and mouse) results indicating strong LDL‑C lowering potential for EDIT‑401, which, if reproduced in humans, could represent a one‑time treatment for hyperlipidemia, including HeFH. For investors, the data mark meaningful preclinical progress for Editas’s lead in‑vivo candidate and support continued development, but do not constitute clinical efficacy or safety in humans. The company’s filing simply discloses the results presented at ASGCT and the press release furnished with the 8‑K.